Blood pressure-lowering drugs in preventing cardiovascular disease Thomas D. Giles Clinical Trials Report 29 November 2009 Pages: 399 - 400
AURORA and JUPITER trials: Recognizing the limitations and expanding the benefits of statin treatment Michael H. Davidson Clinical Trials Report 29 November 2009 Pages: 401 - 403
Characterization and treatment of resistant hypertension Roberto PisoniMustafa I. AhmedDavid A. Calhoun OriginalPaper 29 November 2009 Pages: 407 - 413
Role of ambulatory and home blood pressure recording in clinical practice Nimrta GhumanPatrick CampbellWilliam B. White OriginalPaper 29 November 2009 Pages: 414 - 421
Hypertension and diastolic heart failure Alan H. GradmanJ. Travis Wilson OriginalPaper 29 November 2009 Pages: 422 - 429
Hypertension and atrial fibrillation Orson GoClive Rosendorff OriginalPaper 29 November 2009 Pages: 430 - 435
The current state of RAAS blockade in the treatment of hypertension and proteinuria Rigas G. KalaitzidisGeorge L. Bakris OriginalPaper 29 November 2009 Pages: 436 - 442
Secretory phospholipase A2: A multifaceted family of proatherogenic enzymes Robert S. RosensonMichael H. Gelb OriginalPaper 29 November 2009 Pages: 445 - 451
Emerging inflammatory markers for assessing coronary heart disease risk Marshall A. Corson OriginalPaper 29 November 2009 Pages: 452 - 459
Impaired fasting glucose as a treatment target in diabetes management Rene A. OliverosAdrienne S. ZionRobert Chilton OriginalPaper 29 November 2009 Pages: 460 - 467
Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease William C. CromwellThomas A. Barringer OriginalPaper 29 November 2009 Pages: 468 - 475
Improving risk factor modification: A global approach Tshaka MuchiteniWilliam B. Borden OriginalPaper 29 November 2009 Pages: 476 - 483